
Lorbrena
My Prescription
Payment
Select pharmacy



$7,723.06
$30.00 due at pharmacy
$7,723.06 - $30.00 = $7,693.06
$7,693.06 remaining balance
You will be given your coupon after you complete your purchase with PayPal.
$7,723.06
Print or send this coupon to your phone
About Lorbrena
Drug Details
Lorlatinib, marketed as Lorbrena, is an oral medication designed to treat a specific type of lung cancer known as ALK-positive non-small cell lung cancer (NSCLC) that has metastasized. This drug works by targeting and blocking the anaplastic lymphoma kinase (ALK) protein, which is produced by a gene that, when abnormal, contributes to cancer growth and spread. By inhibiting this protein, Lorlatinib helps to slow or halt the progression of cancer cells. As a pill, it offers a convenient alternative to injections. Potential side effects include swelling in the face, hands, or feet, weight gain, and nerve pain. Always consult your healthcare provider for advice tailored to your health needs before starting any new medication.
Price history for Lorbrena
30 Tablets, 25MG
Average retail price for Lorbrena
Average SaveHealth price for Lorbrena
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Lorbrena dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 25MG | 30 Tablets | $7,723.06 | $257.44 |
| 25MG | 120 Tablets | $30,868.24 | $257.24 |
| 100MG | 30 Tablets | $23,153.12 | $771.77 |
Lorbrena FAQs
Lorlatinib, marketed under the brand name LORBRENA, is used for the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK). It is typically prescribed for patients whose cancer has progressed or who cannot tolerate other ALK inhibitors.
The survival rate for patients taking LORBRENA (lorlatinib) can vary based on several factors, including the stage of the cancer, the patient's overall health, and how well the cancer responds to the treatment. LORBRENA is used to treat non-small cell lung cancer (NSCLC) that is ALK-positive. Clinical trials have shown that LORBRENA can be effective in shrinking tumors and delaying disease progression, but specific survival rates should be discussed with a healthcare provider, as they can provide information tailored to an individual's specific condition and treatment response.
Lorlatinib is not classified as a traditional chemotherapy drug. It is a targeted therapy medication, specifically a tyrosine kinase inhibitor, used to treat certain types of non-small cell lung cancer (NSCLC) that have specific genetic mutations.
Lorlatinib, marketed as LORBRENA, can cause weight gain as a side effect. Patients taking this medication may experience an increase in weight, and it is important for them to monitor any changes and discuss them with their healthcare provider.
Lorviqua, also known as lorlatinib, may cause several side effects. Common side effects include fatigue, weight gain, peripheral neuropathy, cognitive effects, mood changes, and increased cholesterol and triglyceride levels. Other possible side effects are diarrhea, nausea, edema, and joint pain. Serious side effects can include liver problems, lung issues, and heart rhythm changes. It is important for patients to discuss any side effects with their healthcare provider.